GH Research (NASDAQ:GHRS) Trading Up 6.4%

GH Research PLC (NASDAQ:GHRSGet Free Report)’s stock price was up 6.4% during trading on Friday . The company traded as high as $14.53 and last traded at $14.40. Approximately 7,185 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 112,740 shares. The stock had previously closed at $13.53.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on GHRS shares. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of GH Research in a report on Tuesday, May 7th. Canaccord Genuity Group upped their target price on shares of GH Research from $30.00 to $31.00 and gave the company a “buy” rating in a report on Monday, May 6th. Finally, JMP Securities reduced their target price on shares of GH Research from $50.00 to $39.00 and set a “market outperform” rating for the company in a report on Friday, March 1st.

Get Our Latest Analysis on GH Research

GH Research Stock Up 4.1 %

The stock has a market capitalization of $733.10 million, a PE ratio of -22.73 and a beta of 0.80. The firm’s fifty day moving average is $11.81 and its 200-day moving average is $8.76.

GH Research (NASDAQ:GHRSGet Free Report) last posted its quarterly earnings results on Friday, May 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. On average, analysts expect that GH Research PLC will post -0.84 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. PEAK6 Investments LLC increased its holdings in GH Research by 72.9% in the third quarter. PEAK6 Investments LLC now owns 40,308 shares of the company’s stock valued at $405,000 after buying an additional 16,991 shares in the last quarter. AdvisorShares Investments LLC increased its holdings in GH Research by 4.3% in the fourth quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock valued at $280,000 after buying an additional 1,977 shares in the last quarter. Barclays PLC increased its holdings in GH Research by 98.2% in the third quarter. Barclays PLC now owns 63,590 shares of the company’s stock valued at $640,000 after buying an additional 31,500 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in GH Research by 14.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 106,363 shares of the company’s stock valued at $617,000 after buying an additional 13,579 shares in the last quarter. Finally, Lynx1 Capital Management LP increased its holdings in GH Research by 13.8% in the third quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock valued at $11,087,000 after buying an additional 133,804 shares in the last quarter. 56.90% of the stock is owned by hedge funds and other institutional investors.

About GH Research

(Get Free Report)

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

Featured Articles

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.